Key Takeaways
- Revenue growth strong, margins squeezed: US revenue grew 25.7% YoY on volume and launches, but gross margin fell 302 bps YoY to 50.5% as raw material and freight inflation bit hard.
- Pricing environment is a mixed bag: High-single-digit US price erosion persists, though moderating slightly; the company is selectively passing input costs to customers, with more success in OTC than Rx.
- OTC is now the dominant US mix: OTC has shifted from ~49% to 60–65% of US business as management pivots away from volatile, erosion-heavy Rx products.
- The margin recovery story is pushed to next year: Management doubts raw material cost relief will show up in FY23 results due to inventory lags; FY23 EBITDA is guided to 15–16%, with hopes for a better FY24.
- What to watch next quarter: Whether the August price increases stick, the pace of the US OTC mix shift, and any concrete progress on the manufacturing facility acquisition.
US Market: Volume Strength, Price Pain
- Volume engine running: Growth was broad-based across pain, cough & cold, and allergy segments, with the entire basket contributing; some products took a backseat only because price erosion made them uneconomic.
- Pricing erosion moderating but still high: High-single-digit erosion continued at a pace similar to the prior quarter, though management sees a bit of moderation; the environment remains challenging.
- Demand-supply imbalance persists: More supply and capacity exist than demand, which has fallen from COVID peaks; distribution channel consolidation is adding to over-supply and price erosion, and a potential US recession is causing further demand slowdown.
- The OTC pivot is deliberate and structural: Management is shifting mix toward OTC (now 60–65% of US business, up from ~49%) because Rx carries high price erosion and volatility; the company will stop servicing Rx accounts if margins fall below a threshold and re-enter later at a different time.
Mark Saldanha: "Challenges remain in the US. But we are moving against the trend out here and we are trying to differentiate ourselves amongst everyone else."
Margin Walk: Inflation Hits, Relief Delayed
- Gross margin down 302 bps YoY: The decline from 53.5% to 50.5% was driven by increased material costs and freight; sequentially, gross margin improved slightly on product mix and price increases passed to customers.
- Raw material cost jumped ~500 bps QoQ: The Q4-to-Q1 increase was driven by product mix and continued input cost pressure on raw material pricing during the quarter.
- Inventory lag delays any benefit from cooling input prices: Management sees raw material and crude prices coming down but doubts the direct impact will be visible this financial year because the company holds 4+ months of inventory; results may take 6+ months to show.
- Price pass-through is product-by-product: The company tries to pass input costs to customers in parallel; some products see pricing pressure, some are able to pass on increases; Rx is difficult to pass on, while OTC pricing pressure is relatively lower.
- EBITDA margin guided to 15–16% for FY23: Management is hopeful next year will be better if market scenarios and pricing pressures ease, but the migration back to higher levels will take time, not happen overnight.
Mark Saldanha: "I have my doubts whether this financial year you will see the direct impact of all this happening. So hopefully the next year will be much better than this year."
UK, Europe & Rest of World: Broad-Based Growth
- UK revenue jumped to ₹181 crores: Up from a ₹150–155 crore run-rate in the prior 4–5 quarters, driven by better market share and new launches; management sees ₹180 crores per quarter as a fair sustainable assumption with possible slight improvement.
- UK & Europe grew 13.7% YoY: Strong volume growth and new product launches drove the expansion.
- Australia & New Zealand grew 37.8% YoY: The QoQ revenue fall from Q4 FY22 was expected because Q4 had incremental demand on pain management from a COVID flare-up; Q1 numbers indicate the likely trend for the year.
- RoW revenue doubled YoY: Strong growth driven by new product launches and new markets, though the percentage looks large because the base value is small; Access Healthcare contributed only one month (June, ~₹4 crores) and is classified under RoW.
Product Pipeline & Capability Build
- Soft gel and complex oral dosages coming: Four soft gel approvals are expected; the company is also moving into more extended-release solid oral dosage products, which are more complex in nature.
- Creams and ointments are a new segment: Formulations are getting more complex as the company evolves.
- ANDA filing is selective, not volumetric: Management files only with a vision that the product can see light after two years because each ANDA costs a significant sum; the philosophy is not about the number of filings.
- US launches: Nearly 4 products this year, 4 to 5 next year.
- UK launches: 3 to 4 products this year, 6 to 7 next year, from a wish list of nearly 25 products to file in the next 24 months.
- Injectables not on the near-term horizon: Management has its plate full with the current product pipeline and wish list for at least the next 12 months.
Mark Saldanha: "Nowadays ANDAs are not free, so they do charge a huge amount for filings. So, you got to be very selective in your development and filing with a vision that the product can see light after two years."
Capacity, Integration & Capital Allocation
- ₹200 crores CapEx planned: The investment covers new infrastructure for complex molecules and expanding current infrastructure for existing products; it may involve a bit of M&A in the form of the manufacturing facility being pursued; CapEx takes time, with six months to get machines in place.
- Current utilization at 75%: The company is investing in more capacity and machinery expansion to stay ahead of demand.
- Backward integration into API is underway: The aim is to become a fully integrated company; management expects to file at least 2 DMFs this calendar year, maybe 3 in the next financial year; once filed, triggering onto active licenses takes 6–9 months, so hopefully by next year a couple of products will be fully integrated on licenses.
- Access Healthcare acquired for ~₹30 crores: Wholly acquired on 1st June; revenue started flowing in June under RoW; revenue was very close to ₹4 crores in the quarter; plans to tap the Middle East via Access Healthcare's Dubai presence.
- Manufacturing facility acquisition in dialogue: Management hopes in the next couple of months to be in a position to put pen to paper; the greenfield project in Madhya Pradesh will be explored only after closing this transaction.
- Cash balance moved from ~₹349 crores to ₹339 crores: The decline was due to working capital movements and partly the Access Healthcare acquisition of around ₹30 crores.
Mark Saldanha: "So, acquisitions and M&A's are very unpredictable. We don't, unless we are nearing something where we believe there could be a possibility of signing something, it is too early to mention that."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY23 EBITDA margin | 15–16% | FY23 |
| Gross margin level | Remain at Q1 levels | Next 2–3 quarters |
| Revenue milestone | Trending toward ₹2,000 crores | Next year |
| R&D spend increase | Migrate from 2% to 4% of sales | Over next two years |
| API backward integration | File at least 2 DMFs; couple of products fully integrated on licenses | 2 DMFs this calendar year; integration by next year |
| US product launches | ~4 products this year, 4–5 next year | This year and next year |
| UK product launches | 3–4 this year, 6–7 next year | This year and next year |
| UK filings | Wish list of ~25 products | Next 24 months |
| US filings | Wish list of 12–14 products | Next 24 months |
| Capacity expansion | ₹200 crores CapEx for infrastructure and machinery | Next 12–18 months |
| 3-year EBITDA margin target | 19–20% achievable | Over next 3 years |
| Injectables entry | Not in near horizons | At least next 12 months |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Operating revenue | ₹433.8 cr, +24.3% YoY |
| US & North America revenue | ₹173.9 cr, +25.7% YoY |
| EU & UK formulations revenue | ₹181 cr, +13.7% YoY |
| Australia & New Zealand revenue | ₹52.6 cr, +37.8% YoY |
| Rest of World revenue | ₹26.3 cr, +99% YoY |
| Gross margin | 50.5%, declined 302 bps YoY from 53.5% |
| EBITDA | ₹72.9 cr, -5.8% YoY |
| PAT | ₹60.2 cr, vs ₹62.6 cr in Q1 FY22 and ₹29.7 cr in Q4 FY22 |
| R&D spend | ₹8.9 cr, ~2% of sales; target to increase to 4% over next two years |
| Cash and cash equivalents | ₹339 cr as of 30th June 2022 |
| US pricing erosion | High single digits, similar to previous quarter |
| Capacity utilization | ~75% across plants |
| FY23 EBITDA margin guidance | 15–16% anticipated |
| US product launches planned | ~4 products in FY23, 4–5 in FY24 |
| UK product launches planned | 3–4 products in FY23, 6–7 in FY24 |